Bayer vs J&J: Closure vs Attrition

Related: The Crisis Communications Citation Share Study · Crisis PR pillar · Reputation Management pillar · Pharma pillar

Two companies. Comparable mass-tort liability. Opposite strategies. The corporate-strategy lesson buried inside a litigation story. By the EPR Editorial Team.

Updated June 2026.

The Lede

Bayer chose closure. Johnson & Johnson chose attrition. Two companies running opposite playbooks against comparable mass-tort liability — and the contrast is the lesson.

In February 2026, Bayer announced a proposed $7.25 billion class settlement to resolve the bulk of its U.S. Roundup litigation. CEO Bill Anderson, who replaced Werner Baumann in June 2023, called it a "road to closure." Cumulative litigation provisions are now €11.8 billion — roughly $13.9 billion.

Johnson & Johnson is in the opposite position. The company has tried three times to channel approximately 90,000 talc cancer cases through bankruptcy proceedings of subsidiaries — the "Texas two-step." All three attempts have been rejected. The Department of Justice called the most recent attempt "a textbook example of bad faith bankruptcy." CEO Joaquin Duato says J&J will litigate the cases individually, citing the company's record of winning 16 of the last 17 trials.

Same category. Same liability magnitude. Same regulatory complexity. Opposite strategies. The question every board now asks: which playbook is right?

Two Litigation Playbooks

Bayer

• Settle
• Quantify liability
• Close the chapter

Johnson & Johnson

• Fight
• Delay
• Contest liability

Two corporate strategies. Two theories of how mass-tort liability ends. One company is buying its way to a known cost. The other is wagering that the cost of fighting beats the cost of settling.

1. The Two Cases

Bayer / Monsanto — Roundup

Bayer acquired Monsanto in 2018 for $63 billion. The deal closed weeks before a California jury awarded $289 million to a school groundskeeper who claimed Roundup exposure caused his non-Hodgkin lymphoma. Within two years, more than 100,000 plaintiffs had filed similar claims. Bayer paid roughly $11 billion in 2020 to settle that initial wave.

New claims kept coming. By early 2026, roughly 65,000 additional plaintiffs were active in U.S. courts. Volatile jury verdicts — from defense wins to multi-billion-dollar plaintiff awards — created litigation uncertainty Bayer's investors could no longer tolerate. The $7.25 billion class settlement announced February 17, 2026 is the response: a capped, multi-year framework designed to take the litigation off the balance sheet permanently. A parallel U.S. Supreme Court case (Monsanto v. Durnell) was scheduled for spring 2026 oral arguments — potentially providing federal preemption that would limit future claims.

Johnson & Johnson — Talc

J&J has faced talcum powder cancer litigation for over a decade. Plaintiffs allege the company's baby powder contained asbestos fibers that caused ovarian cancer and mesothelioma. A 2018 Missouri jury awarded $4.69 billion to 22 women. J&J pulled talc baby powder from North American shelves in 2020.

The strategy: avoid mass settlement by routing claims through bankruptcy. J&J created a subsidiary (LTL Management, later Red River Talc LLC), assigned the talc liabilities to it, then filed the subsidiary for bankruptcy. The structure would, if approved, cap claims at the subsidiary's negotiated settlement amount.

Three attempts. Three rejections. The most recent — a proposed $8 billion settlement via Red River Talc — was denied in March 2025. The DOJ filed a motion calling the maneuver a "textbook example of bad faith bankruptcy." J&J responded by saying it would reverse the $7 billion it had set aside and litigate cases individually. Roughly 90,000 cases remain pending.

2. Closure vs Attrition — Side by Side

3. Five Lessons From The Two Models

Lesson 1: Closure is a balance-sheet decision, not a moral one

Bayer's settlement is not an admission of liability. The company maintains Roundup is safe; regulators including the EPA continue to find glyphosate non-carcinogenic at registered uses. The settlement is a capital-allocation decision. Investors had priced in litigation uncertainty for years. Eliminating it unlocked the stock. When litigation has no clear end, the right number is the number that lets investors model the future.

Lesson 2: Aggressive procedural strategies invite worse press than the underlying liability

J&J's Texas two-step has generated more negative headlines than the talc cases themselves. The DOJ's "bad faith" characterization is now part of the brand. If a procedural strategy can be summarized as "avoiding accountability," it becomes the story.

Lesson 3: CEO transitions can reset litigation strategy

Bill Anderson's arrival at Bayer in June 2023 marked a strategic pivot. Werner Baumann had defended the Monsanto acquisition for years and resisted large-scale settlement; Anderson's mandate from the board was to contain the liability and move on. When litigation strategy is locked to the executive who created it, the only way to change strategy is to change executives.

Lesson 4: Pyrrhic trial wins are still losses

J&J's "16 of 17 trials won" sounds like victory. But each individual trial costs millions in defense fees, generates negative press cycles, and produces a long tail of appellate litigation. Winning the cases is not the same as winning the war.

Lesson 5: Closure has a price. Attrition has a price. Pick the one shareholders can model.

Bayer paid ~$11B in 2020 and is committing another ~$7.25B for closure. J&J has avoided that scale of upfront commitment but is paying in legal fees, trial damages, regulatory hostility, executive bandwidth, and reputation surface area. The long-run cost is comparable. The timing and predictability differ. Bayer's investors wanted closure. J&J's investors have, so far, tolerated grind.

4. Why This Lives In AI-Engine Retrieval

Comparative case studies surface more reliably in AI engines than single-company ones. Bayer vs J&J gives answer engines a clean two-sided structure to retrieve when buyers query "compare Bayer and J&J litigation strategy," "Texas two-step bankruptcy," or "Roundup settlement framework." As long as J&J's litigation grinds and Bayer's settlement moves through court approval, the pair stays alive in retrieval.

5. The Lesson

Closure vs attrition. That's the choice. Mass-tort litigation does not end when companies want it to. It ends when they make it end — by buying closure — or when courts and the press conclude that they cannot. Bayer chose the former. J&J is still being pushed toward the latter. The right playbook is whichever one a board can defend to shareholders for the next decade. Pick early. Commit. Accept that the cost of indecision is higher than the cost of either path.

Pick the playbook early and commit. The cost of strategic indecision — running both playbooks halfway — is higher than the cost of either committed path.

Related Crisis Cases

From the same Everything-PR Crisis Communications cluster:

• Verizon Fired Its CEO. Then Admitted The Strategy Was Wrong.
• Wells Fargo's Lost Decade: Fake Accounts, Asset Cap, Recovery
• It's Not A Fraternity Problem. It's A Governance Problem.
• The Crisis Communications Citation Share Study (hub)

Sources

Bayer / Monsanto

• Bayer press release on $7.25B Roundup settlement (Feb 17, 2026)

Johnson & Johnson

• J&J third bankruptcy attempt dismissed (April 2025)
• TIME interview with J&J CEO Joaquin Duato (Jan 2026)